MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-03-2026
Aytu BioScience Deferred Revenue 2011-2026 | AYTU
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Aytu BioScience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 339 K | - | - | - | - | 85.7 K | 85.7 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 339 K | 85.7 K | 170 K |
Quarterly Deferred Revenue Aytu BioScience
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | 100 K | 100 K | 400 K | 100 K | 200 K | 200 K | 200 K | 200 K | 476 K | 233 K | 339 K | 339 K | - | - | - | - | 14 K | - | 14 K | - | - | - | - | - | - | - | - | 85.7 K | 85.7 K | 85.7 K | 85.7 K | 85.7 K | - | 85.7 K | 85.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 476 K | 14 K | 167 K |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
227 K | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
1.85 M | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
33.3 K | $ 3.62 | -1.09 % | $ 8.71 B |  Australia |
 |
BioNTech SE
BNTX
|
300 M | $ 98.41 | 1.77 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
563 K | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
124 K | - | 2.54 % | $ 160 B |  France |
 |
Aligos Therapeutics
ALGS
|
151 K | $ 8.74 | 0.23 % | $ 86.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Therapeutics
APLT
|
667 K | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
4.41 M | - | -13.39 % | $ 1.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
643 K | $ 21.38 | 0.09 % | $ 999 M | USA |
 |
Advaxis
ADXS
|
165 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
2.68 M | $ 1.56 | 6.12 % | $ 401 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
6.3 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 3.05 | 4.45 % | $ 5.02 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
1.09 M | $ 4.15 | -0.95 % | $ 444 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
2.62 M | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
957 K | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
1.72 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
187 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Evogene Ltd.
EVGN
|
119 K | $ 0.82 | 0.02 % | $ 27.9 M | Israel |
 |
bluebird bio
BLUE
|
2.28 M | - | - | $ 546 M | USA |
 |
CureVac N.V.
CVAC
|
158 M | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
9.8 M | - | - | $ 1.41 B | USA |
 |
Alpine Immune Sciences
ALPN
|
35.6 M | - | - | $ 2.17 B | USA |